175 related articles for article (PubMed ID: 20199178)
1. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
Roozbeh J; Banihashemi MA; Ghezlou M; Afshariani R; Salari S; Moini M; Sagheb MM
Ren Fail; 2010 Jan; 32(2):172-8. PubMed ID: 20199178
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Aminorroaya A; Janghorbani M; Rezvanian H; Aminian T; Gharavi M; Amini M
Nephron Clin Pract; 2005; 99(3):c73-7. PubMed ID: 15665549
[TBL] [Abstract][Full Text] [Related]
3. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
[TBL] [Abstract][Full Text] [Related]
4. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; García J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
5. [Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study].
Hay U; Ludvik B; Gisinger C; Schernthaner G
Schweiz Med Wochenschr; 1988 Feb; 118(5):165-9. PubMed ID: 3278375
[TBL] [Abstract][Full Text] [Related]
6. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
7. Effect of captopril on heavy proteinuria in azotemic diabetics.
Taguma Y; Kitamoto Y; Futaki G; Ueda H; Monma H; Ishizaki M; Takahashi H; Sekino H; Sasaki Y
N Engl J Med; 1985 Dec; 313(26):1617-20. PubMed ID: 3906398
[TBL] [Abstract][Full Text] [Related]
8. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
Lewis EJ; Hunsicker LG; Bain RP; Rohde RD
N Engl J Med; 1993 Nov; 329(20):1456-62. PubMed ID: 8413456
[TBL] [Abstract][Full Text] [Related]
9. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
10. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
13. [The effect of blood pressure-reducing therapy with captopril on tubular marker excretion in type-1 diabetics with nephropathy].
Ratzmann KP; Raskovic M; Schimke E
Dtsch Med Wochenschr; 1994 Jun; 119(22):796-800. PubMed ID: 8205941
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
15. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy.
Aggarwal HK; Jain D; Talapatra P; Yadav RK; Gupta T; Kathuria KL
Ren Fail; 2010; 32(8):941-6. PubMed ID: 20722561
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition.
Vora JP; Leese GP; Peters JR; Owens DR
J Diabetes Complications; 1996; 10(2):88-93. PubMed ID: 8777336
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
